EDITORIAL

doi:10.1111/add.12893

Treating substance use disorders in patients with hepatitis C Substance use disorders are prevalent among people with hepatitis C virus (HCV) and adversely affect HCV management. Addressing this comorbidity is paramount as more effective HCV treatment options emerge. Existing screening tools and treatment options for addressing the spectrum of substance use disorders have the potential to improve HCV treatment outcomes HCV PREVALENCE AND TREATMENT Between 2 and 3% (130–170 million) of the global population has been infected with the hepatitis C virus (HCV) [1], which is associated with progressive liver fibrosis and endstage liver disease [2]. Further, cirrhosis from HCV is the leading indication for liver transplantation world-wide and in the United Kingdom, Australia, Canada and the United States. Achieving sustained virological response (SVR, a marker of virological clearance) has been to shown to markedly reduce mortality and morbidity from HCVassociated liver disease. Comorbid psychiatric conditions including substance use disorders (SUDs) remain significant barriers to HCV treatment and require that providers be prepared to address these conditions to optimize care. Starting in late 2013, HCVantiviral therapy moved into the interferon-free all-oral therapy era. The US Food and Drug Administration has approved four all-oral regimens, and more therapeutic options are expected [3]. Weekly injectable pegylated interferon for 24–48 weeks was once the mainstay of therapy, complicating regimens with exacerbation or precipitation of underlying psychiatric conditions. New oral regimens promise higher SVR rates in shorter duration (8–24 weeks) and fewer neuropsychiatric side effects. Consequently, some subgroup conditions thought previously to be relative contraindications for therapy (i.e. history of severe depression) are now potentially eligible for HCV treatment. However, the detection and treatment of SUDs remain an important component of HCV treatment guidelines for optimizing care in this patient population [4]. IMPACT OF SUDS ON HCV MANAGEMENT SUDs are highly prevalent among people with HCV. Among patients with HCV, 58–78% had a life-time (past or present) drug or alcohol use disorder [5,6], while 21% of out-patients screened positive for current heavy drinking [6]. In a study of privately insured patients with HCV, 93% reported consuming alcohol prior to their HCV diagnosis, © 2015 Society for the Study of Addiction

while 64% reported risky drinking prior to receiving HCV treatment [7]. High rates of SUDs observed in this population pose a significant challenge for providers in managing HCV. Comorbid SUDs can impact HCV management adversely, with challenges ranging from complicating access to HCV treatment to reducing treatment effectiveness. Patients with active intravenous drug abuse are less likely and willing to seek HCV treatment [8]. Patients with alcohol use disorders are less likely to be eligible for and/or complete HCV treatment, reducing the likelihood of SVR [9]. Furthermore, excessive alcohol use remains a major cause of liver disease and cirrhosis, even in the absence of HCV. These findings highlight the importance of detecting and treating SUDs in this patient population.

SUD SCREENING Brief screening instruments to identify existing SUDs are used world-wide. The Alcohol Use Disorders Identification Test (AUDIT) is used in Brazil, South Africa, the United Kingdom and the United States to screen for alcohol misuse. The US Department of Veterans Affairs (VA) mandates the use of the three consumption items of the AUDIT (or AUDIT-C) as a screening tool for identifying alcohol misuse in out-patients [10]. The AUDIT-C has been shown to accurately detect risky drinking, defined as drinking above recommended gender-specific limits set by the National Institute on Alcohol Abuse and Alcoholism, in out-patients [10]. Similarly, researchers at Boston University have found that a single-item drug screener, ‘How many times in the past year have you used an illegal drug or used prescription medication for non-medical reasons?’, is also accurate for detecting current illicit drug use and drug use disorders among patients presenting to primary care [11]. The brief nature of these screening instruments makes them well suited for use in busy out-patient clinics, as they can be completed quickly, by various means including paper or computer, and without the need for provider involvement. The results of these screening instruments can also provide the clinical benefit of indicating an appropriate course of SUD treatment. For example, scores on the AUDIT-C indicating risky (but not dependent) drinking may suggest the use of a brief alcohol intervention (BAI), while scores indicating probable alcohol dependence suggest the need for more intensive addiction treatment [12]. Addiction, 110, 1057–1059

1058

Editorial

SUD TREATMENT Providers have several options for treating SUDs in patients with HCV. BAIs have long been considered to be a low-cost, effective frontline intervention for patients screening positive for risky drinking [13]. They are also well suited to the out-patient clinic setting, as they are brief (ranging from a 10–15-minute single session to four sessions) in nature and can be administered by a computer or provider. BAIs typically consist of personalized feedback that includes normative comparisons of drinking behavior and psychoeducation about the consequences of alcohol misuse. Research shows that BAIs can reduce weekly alcohol consumption and result in fewer heavy drinking episodes 1 year post-intervention in out-patient populations [13]. Unfortunately, the evidence for the effectiveness of brief interventions for reducing drug use remains limited [14]. Patients with alcohol dependence often require more intensive addiction treatment. This poses a significant challenge for clinics that operate on limited resources, including little available staff time, expertise and knowledge and availability of addiction treatment options. Within-clinic SUD interventions are possible [15], but referral to addiction treatment will probably remain the most feasible method for clinics to support patients with comorbid SUDs. However, challenges to linking patients to addiction treatment are well documented and include fear of treatment, privacy concerns and poor treatment availability [16]. Overcoming these barriers through case management [17] or other brief, potentially low-cost interventions to promote linkage to addiction treatment is paramount for optimizing the management of HCV. Improving linkage to addiction treatment in the United States will be especially important in the context of the Affordable Care Act, which promises greater access to SUD care, particularly for patients with limited financial resources [18]. In summary, SUDs are endemic in patients with HCV and represent a significant proportion of the treatmentnaive cohort. As antiviral therapies have now evolved to high efficacy, with shorter duration and fewer side effects, more rapid identification and mitigation of patient comorbid conditions including SUDs is becoming increasingly paramount, as well as the treatment of alcohol use disorders with or without HCV to prevent cirrhosis. Declaration of interests Dr Cheung has received research funding from Gilead Sciences. Acknowledgements This material is based upon work supported by the Department of Veterans Affairs, Veterans Health © 2015 Society for the Study of Addiction

Administration, Office of Research and Development, Health Services Research and Development (CRE 12009), to Dr Cucciare. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. Keywords Hepatitis C, out-patient care, substance use disorders, treatment outcome. 1,2,3

MICHAEL A. CUCCIARE

4,5

, RAMSEY C. CHEUNG

&

6,7

CATHERINE RONGEY

Center for Mental Healthcare and Outcomes Research, Central Arkansas Veterans Affairs Healthcare System, 1

North Little Rock, AR, USA, Veterans Affairs South Central (VISN 16) Mental Illness Research Education, and Clinical Center, Central Arkansas 2

Veterans Healthcare System, North Little Rock, AR , USA, Department of Psychiatry University of Arkansas for Medical Sciences Little Rock, 3

AR , USA, Division of Gastroenterology and Hepatology Veterans Affairs 4

Palo Alto Health Care System Palo Alto, CA, USA, Stanford University 5

Stanford, CA, USA, San Francisco Veterans Affairs Health Care System 6

San Francisco, CA 94121, USA, Department of Medicine University of 7

California San Francisco San Francisco, CA, USA . E-mail: [email protected]

References 1. Centers for Disease Control and Prevention (CDC). Infectious disease related to travel. 2015. Available at: http://wwwnc. cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/hepatitis-c (accessed 3 February 2015). 2. El-Serag H. B. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002; 36: S74–83. 3. American Association for the Study of Liver Diseases. Recommendations for testing, managing, and treating hepatitis C. 2015. Available at: http://www.hcvguidelines.org/ (accessed 4 February 2015). 4. Yee H. S., Chang M. F., Pocha C., Lim J., Ross D., Morgan T. R. et al. Update on management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol 2012; 107: 669–89. 5. El-Serag H. B., Kunik M., Richardson P., Rabeneck L. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology 2002; 123: 476–82. 6. Fireman M., Indest D. W., Blackwell A., Whitehead A. J., Hauser P. Addressing tri-morbidity (hepatitis C, psychiatric disorders, and substance use): the importance of routine mental health screening as a component of comanagement model of care. Clin Infect Dis 2005; 40: S286–91. 7. Russell M., Pauly M. P., Moore C. D., Chia C., Dorrell J., Cunanan R. J. et al. The impact of lifetime alcohol use on hepatits C treatment outcomes in privately insured members of an integrated health care plan. Hepatology 2012; 56: 1223–30. 8. Grebely J., Genoway K. A., Raffa J. D., Dhadwal G., Rajan T., Showler G. et al. Barriers associated with the treatment of Addiction, 110, 1057–1059

Editorial

9.

10.

11.

12.

13.

hepatitis C virus infection among illicit drug users. Drug Alcohol Depend 2008; 93: 141–7. Anand B. S., Currie S., Dieperink E., Bini E. J., Shen H., Ho S. B. et al. Alcohol use and treatment of hepatitis C virus: results of a national multicenter study. Gastroenterology 2006; 130: 1607–16. Bradley K. A., DeBenedetti A. F., Volk R. J., Williams E. C., Frank D., Kivlahan D. R. AUDIT-C as a brief screen for alcohol misuse in primary care. Alcohol Clin Exp Res 2007; 31: 1208–17. Smith P. C., Schmidt S. M., Allensworth-Davies D., Saitz R. A single-question screening test for drug use in primary care. Arch Intern Med 2010; 170: 1155–60. Glass J. E., Perron B. E., Ilgen M. A., Chermack S. T., Ratliff S., Zivin K. Prevalence and correlates of specialty substance use disorder treatment for Department of Veterans Affairs Healthcare System patients with high alcohol consumption. Drug Alcohol Depend 2010; 112: 150–5. Jonas D. E., Garbutt J. C., Amick H. R., Brown J. M., Brownley K. A., Council C. L. et al. Behavioral counseling after screening

© 2015 Society for the Study of Addiction

14. 15.

16.

17.

18.

1059

for alcohol misuse in primary care: a systematic review and meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2012; 157: 645–54. Saitz R. Screening and brief intervention for unhealthy drug use: little to no efficacy. Front Psychiatry 2014; 5: 121. Dieperink E., Fuller B., Isenhart C., McMaken K., Lenox R., Pocha C. et al. Efficacy of motivational enhancement therapy on alcohol use disorders in patients with chronic hepatitis C: a randomized controlled trial. Addiction 2014; 109: 1869–77. Rapp R. C. Treatment barriers identified by substance abusers assessed at a centralized intake unit. J Subst Abuse Treat 2006; 30: 227–35. Rapp R. C., Otto A. L., Lane T., Redko C., McGatha S., Carlson R. G. Improving linkage with substance abuse treatment using brief case management and motivational interviewing. Drug Alcohol Depend 2008; 94: 172–82. Humphreys K., Frank R. G. The Affordable Care Act will revolutionize care for substance use disorders in the United States. Addiction 2014; 109: 1957–8.

Addiction, 110, 1057–1059

Treating substance use disorders in patients with hepatitis C.

Treating substance use disorders in patients with hepatitis C. - PDF Download Free
85KB Sizes 3 Downloads 12 Views